Fulcrum Therapeutics, Inc.·4

Jan 10, 4:30 PM ET

Rajavelu Esther 4

4 · Fulcrum Therapeutics, Inc. · Filed Jan 10, 2022

Insider Transaction Report

Form 4
Period: 2022-01-03
Rajavelu Esther
Chief Financial Officer
Transactions
  • Award

    Stock Option (right to buy)

    2022-01-03+200,000200,000 total
    Exercise: $17.82Exp: 2032-01-02Common Stock (200,000 underlying)
Footnotes (1)
  • [F1]This option was granted on January 3, 2022 and is scheduled to vest 25% on the first anniversary of the vesting commencement date of January 3, 2022. The remainder of the shares underlying the grant shall vest in equal quarterly installments over the following three years until the fourth anniversary of the vesting commencement date, subject to continued service.

Documents

1 file
  • 4
    doc4.xmlPrimary

    FORM 4 SUBMISSION